Cargando…

Diagnostic Performance of 2018 KLCA-NCC Practice Guideline for Hepatocellular Carcinoma on Gadoxetic Acid-Enhanced MRI in Patients with Chronic Hepatitis B or Cirrhosis: Comparison with LI-RADS Version 2018

OBJECTIVE: To evaluate the performance of the 2018 Korean Liver Cancer Association-National Cancer Center (KLCA-NCC) Practice Guidelines (hereafter, PG) for the diagnosis of hepatocellular carcinoma (HCC) using gadoxetic acid-enhanced MRI, compared to the Liver Imaging-Reporting and Data System (LI-...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Sang Min, Lee, Jeong Min, Ahn, Su Joa, Kang, Hyo-Jin, Yang, Hyun Kyung, Yoon, Jeong Hee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Radiology 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8236366/
https://www.ncbi.nlm.nih.gov/pubmed/33739633
http://dx.doi.org/10.3348/kjr.2020.0846
_version_ 1783714522448527360
author Lee, Sang Min
Lee, Jeong Min
Ahn, Su Joa
Kang, Hyo-Jin
Yang, Hyun Kyung
Yoon, Jeong Hee
author_facet Lee, Sang Min
Lee, Jeong Min
Ahn, Su Joa
Kang, Hyo-Jin
Yang, Hyun Kyung
Yoon, Jeong Hee
author_sort Lee, Sang Min
collection PubMed
description OBJECTIVE: To evaluate the performance of the 2018 Korean Liver Cancer Association-National Cancer Center (KLCA-NCC) Practice Guidelines (hereafter, PG) for the diagnosis of hepatocellular carcinoma (HCC) using gadoxetic acid-enhanced MRI, compared to the Liver Imaging-Reporting and Data System (LI-RADS) version 2018 (hereafter, v2018). MATERIALS AND METHODS: From January 2013 to October 2015, treatment-naïve hepatic lesions (≥ 1 cm) on gadoxetic acid-enhanced MRI in consecutive patients with chronic hepatitis B or cirrhosis were retrospectively evaluated. For each lesion, three radiologists independently analyzed the imaging features and classified the lesions into categories according to the 2018 KLCA-NCC PG and LI-RADS v2018. The imaging features and categories were determined by consensus. Generalized estimating equation (GEE) models were used to compare the per-lesion diagnostic performance of the 2018 KLCA-NCC PG and LI-RADS v2018 using the consensus data. RESULTS: In total, 422 lesions (234 HCCs, 45 non-HCC malignancies, and 143 benign lesions) from 387 patients (79% male; mean age, 59 years) were included. In all lesions, the definite HCC (2018 KLCA-NCC PG) had a higher sensitivity and lower specificity than LR-5 (LI-RADS v2018) (87.2% [204/234] vs. 80.8% [189/234], p < 0.001; 86.2% [162/188] vs. 91.0% [171/188], p = 0.002). However, in lesions of size ≥ 2 cm, the definite HCC had a higher sensitivity than the LR-5 (86.8% [164/189] vs. 82.0 (155/189), p = 0.002) without a reduction in the specificity (80.0% [48/60] vs. 83.3% [50/60], p = 0.15). In all lesions, the sensitivity and specificity of the definite/probable HCC (2018 KLCA-NCC PG) and LR-5/4 did not differ significantly (89.7% [210/234] vs. 91.5% [214/234], p = 0.204; 83.5% [157/188] vs. 79.3% [149/188], p = 0.071). CONCLUSION: For the diagnosis of HCC of size ≥ 2 cm, the definite HCC (2018 KLCA-NCC PG) had a higher sensitivity than LR-5, without a reduction in specificity. The definite/probable HCC (2018 KLCA-NCC PG) had a similar sensitivity and specificity to that those of the LR-5/4.
format Online
Article
Text
id pubmed-8236366
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Korean Society of Radiology
record_format MEDLINE/PubMed
spelling pubmed-82363662021-07-07 Diagnostic Performance of 2018 KLCA-NCC Practice Guideline for Hepatocellular Carcinoma on Gadoxetic Acid-Enhanced MRI in Patients with Chronic Hepatitis B or Cirrhosis: Comparison with LI-RADS Version 2018 Lee, Sang Min Lee, Jeong Min Ahn, Su Joa Kang, Hyo-Jin Yang, Hyun Kyung Yoon, Jeong Hee Korean J Radiol Gastrointestinal Imaging OBJECTIVE: To evaluate the performance of the 2018 Korean Liver Cancer Association-National Cancer Center (KLCA-NCC) Practice Guidelines (hereafter, PG) for the diagnosis of hepatocellular carcinoma (HCC) using gadoxetic acid-enhanced MRI, compared to the Liver Imaging-Reporting and Data System (LI-RADS) version 2018 (hereafter, v2018). MATERIALS AND METHODS: From January 2013 to October 2015, treatment-naïve hepatic lesions (≥ 1 cm) on gadoxetic acid-enhanced MRI in consecutive patients with chronic hepatitis B or cirrhosis were retrospectively evaluated. For each lesion, three radiologists independently analyzed the imaging features and classified the lesions into categories according to the 2018 KLCA-NCC PG and LI-RADS v2018. The imaging features and categories were determined by consensus. Generalized estimating equation (GEE) models were used to compare the per-lesion diagnostic performance of the 2018 KLCA-NCC PG and LI-RADS v2018 using the consensus data. RESULTS: In total, 422 lesions (234 HCCs, 45 non-HCC malignancies, and 143 benign lesions) from 387 patients (79% male; mean age, 59 years) were included. In all lesions, the definite HCC (2018 KLCA-NCC PG) had a higher sensitivity and lower specificity than LR-5 (LI-RADS v2018) (87.2% [204/234] vs. 80.8% [189/234], p < 0.001; 86.2% [162/188] vs. 91.0% [171/188], p = 0.002). However, in lesions of size ≥ 2 cm, the definite HCC had a higher sensitivity than the LR-5 (86.8% [164/189] vs. 82.0 (155/189), p = 0.002) without a reduction in the specificity (80.0% [48/60] vs. 83.3% [50/60], p = 0.15). In all lesions, the sensitivity and specificity of the definite/probable HCC (2018 KLCA-NCC PG) and LR-5/4 did not differ significantly (89.7% [210/234] vs. 91.5% [214/234], p = 0.204; 83.5% [157/188] vs. 79.3% [149/188], p = 0.071). CONCLUSION: For the diagnosis of HCC of size ≥ 2 cm, the definite HCC (2018 KLCA-NCC PG) had a higher sensitivity than LR-5, without a reduction in specificity. The definite/probable HCC (2018 KLCA-NCC PG) had a similar sensitivity and specificity to that those of the LR-5/4. The Korean Society of Radiology 2021-07 2021-03-09 /pmc/articles/PMC8236366/ /pubmed/33739633 http://dx.doi.org/10.3348/kjr.2020.0846 Text en Copyright © 2021 The Korean Society of Radiology https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Gastrointestinal Imaging
Lee, Sang Min
Lee, Jeong Min
Ahn, Su Joa
Kang, Hyo-Jin
Yang, Hyun Kyung
Yoon, Jeong Hee
Diagnostic Performance of 2018 KLCA-NCC Practice Guideline for Hepatocellular Carcinoma on Gadoxetic Acid-Enhanced MRI in Patients with Chronic Hepatitis B or Cirrhosis: Comparison with LI-RADS Version 2018
title Diagnostic Performance of 2018 KLCA-NCC Practice Guideline for Hepatocellular Carcinoma on Gadoxetic Acid-Enhanced MRI in Patients with Chronic Hepatitis B or Cirrhosis: Comparison with LI-RADS Version 2018
title_full Diagnostic Performance of 2018 KLCA-NCC Practice Guideline for Hepatocellular Carcinoma on Gadoxetic Acid-Enhanced MRI in Patients with Chronic Hepatitis B or Cirrhosis: Comparison with LI-RADS Version 2018
title_fullStr Diagnostic Performance of 2018 KLCA-NCC Practice Guideline for Hepatocellular Carcinoma on Gadoxetic Acid-Enhanced MRI in Patients with Chronic Hepatitis B or Cirrhosis: Comparison with LI-RADS Version 2018
title_full_unstemmed Diagnostic Performance of 2018 KLCA-NCC Practice Guideline for Hepatocellular Carcinoma on Gadoxetic Acid-Enhanced MRI in Patients with Chronic Hepatitis B or Cirrhosis: Comparison with LI-RADS Version 2018
title_short Diagnostic Performance of 2018 KLCA-NCC Practice Guideline for Hepatocellular Carcinoma on Gadoxetic Acid-Enhanced MRI in Patients with Chronic Hepatitis B or Cirrhosis: Comparison with LI-RADS Version 2018
title_sort diagnostic performance of 2018 klca-ncc practice guideline for hepatocellular carcinoma on gadoxetic acid-enhanced mri in patients with chronic hepatitis b or cirrhosis: comparison with li-rads version 2018
topic Gastrointestinal Imaging
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8236366/
https://www.ncbi.nlm.nih.gov/pubmed/33739633
http://dx.doi.org/10.3348/kjr.2020.0846
work_keys_str_mv AT leesangmin diagnosticperformanceof2018klcanccpracticeguidelineforhepatocellularcarcinomaongadoxeticacidenhancedmriinpatientswithchronichepatitisborcirrhosiscomparisonwithliradsversion2018
AT leejeongmin diagnosticperformanceof2018klcanccpracticeguidelineforhepatocellularcarcinomaongadoxeticacidenhancedmriinpatientswithchronichepatitisborcirrhosiscomparisonwithliradsversion2018
AT ahnsujoa diagnosticperformanceof2018klcanccpracticeguidelineforhepatocellularcarcinomaongadoxeticacidenhancedmriinpatientswithchronichepatitisborcirrhosiscomparisonwithliradsversion2018
AT kanghyojin diagnosticperformanceof2018klcanccpracticeguidelineforhepatocellularcarcinomaongadoxeticacidenhancedmriinpatientswithchronichepatitisborcirrhosiscomparisonwithliradsversion2018
AT yanghyunkyung diagnosticperformanceof2018klcanccpracticeguidelineforhepatocellularcarcinomaongadoxeticacidenhancedmriinpatientswithchronichepatitisborcirrhosiscomparisonwithliradsversion2018
AT yoonjeonghee diagnosticperformanceof2018klcanccpracticeguidelineforhepatocellularcarcinomaongadoxeticacidenhancedmriinpatientswithchronichepatitisborcirrhosiscomparisonwithliradsversion2018